当前位置: X-MOL 学术Diabetes Obes. Metab. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical use of a 180-day implantable glucose sensor improves glycated haemoglobin and time in range in patients with type 1 diabetes.
Diabetes, Obesity and Metabolism ( IF 5.4 ) Pub Date : 2020-02-09 , DOI: 10.1111/dom.13993
Concetta Irace 1 , Antonio Cutruzzolà 2 , Annamaria Nuzzi 3 , Roberta Assaloni 4 , Barbara Brunato 4 , Dario Pitocco 5 , Linda Tartaglione 5 , Sergio Di Molfetta 6 , Angelo Cignarelli 6 , Luigi Laviola 6 , Giuseppe Citro 7 , Elisabetta Lovati 8 , Agostino Gnasso 2 , Katherine S Tweden 9 , Francine R Kaufman 9
Affiliation  

This real‐world study evaluated the changes in glycated haemoglobin (HbA1c) and continuous glucose monitoring (CGM) metrics associated with use of the implantable 180‐day Eversense CGM System (Eversense) in patients with type 1 diabetes.

中文翻译:

180天植入式葡萄糖传感器的临床使用可改善1型糖尿病患者的糖化血红蛋白水平和时间。

这项真实世界的研究评估了1型糖尿病患者与使用可植入180天Eversense CGM系统(Eversense)相关的糖化血红蛋白(HbA1c)和连续葡萄糖监测(CGM)指标的变化。
更新日期:2020-02-09
down
wechat
bug